Clinical trial
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
NCT00243763 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00243763 |
|---|---|
| Title | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma |
| Official title | Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | TKI258 |
| Enrollment | 64 |
| First posted | Oct 25, 2005 |
| Last update posted | Nov 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: